Healthcare -
Medical - Healthcare Information Services - NASDAQ - US
$ 91.61
2.03 %
$ 2.61 B
Market Cap
-65.91
P/E
1. INTRINSIC VALUE
Balance Sheet
GeneDx Holdings Corp.
| Current Assets | 198 M |
| Cash & Short-Term Investments | 141 M |
| Receivables | 37.6 M |
| Other Current Assets | 19.2 M |
| Non-Current Assets | 221 M |
| Long-Term Investments | 0 |
| PP&E | 58.5 M |
| Other Non-Current Assets | 163 M |
| Current Liabilities | 54.8 M |
| Accounts Payable | 7.95 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 46.9 M |
| Non-Current Liabilities | 119 M |
| Long-Term Debt | 51.9 M |
| Other Non-Current Liabilities | 67.4 M |
EFFICIENCY
Earnings Waterfall
GeneDx Holdings Corp.
| Revenue | 305 M |
| Cost Of Revenue | 111 M |
| Gross Profit | 194 M |
| Operating Expenses | 214 M |
| Operating Income | -23.2 M |
| Other Expenses | 29.1 M |
| Net Income | -52.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GeneDx Holdings Corp.
| Net Income | -52.3 M |
| Depreciation & Amortization | 22 M |
| Capital Expenditures | -5.49 M |
| Stock-Based Compensation | 9.14 M |
| Change in Working Capital | 0 |
| Others | -6.96 M |
| Free Cash Flow | -34 M |
Wall Street Analysts Price Targets
GeneDx Holdings Corp.
Wall Street analysts predict an average 1-year price target for WGS of $48 , with forecasts ranging from
a
low of
$34 to a high of $70 .
WGS Lowest Price Target
Wall Street Target
34 USD
-62.89%
WGS Average Price Target
Wall Street Target
48 USD
-47.60%
WGS Highest Price Target
Wall Street Target
70 USD
-23.59%
4. DIVIDEND
ANALYSIS
WGS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
GeneDx Holdings Corp.
Sold
0-3 MONTHS
9.24 M USD 2
3-6 MONTHS
15.5 M USD 2
6-9 MONTHS
86.6 M USD 4
9-12 MONTHS
28.4 M USD 3
Bought
8.61 M USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
globenewswire.com
- 6 days ago
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.
marketbeat.com
- 1 week ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
globenewswire.com
- 1 week ago
Why GeneDX Stock Surged Higher This Week
Shares in genetic testing company GeneDx Holdings (WGS 0.74%) continued their wild ride in 2025 and are up almost 34% on the week to Friday morning. This week's move follows the American Academy of Pediatrics' (AAP) updated guidance, which recommends exome and genetic testing as a first-line test for children with global developmental delays (GDDs) and intellectual disabilities (IDs).
fool.com
- 1 week ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
globenewswire.com
- 1 week ago
Insiders Invested Millions in these Five Rebounding Stocks
Marriott Vacations Worldwide director Christian Asmar bought 412,449 shares for just over $27.88 million.
247wallst.com
- 1 week ago
GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in partnership with the clinical genetics team at Seattle Children's supporting the application of rapid exome sequencing (rES) and rapid genome sequencing (rGS) as a first-tier test for non-critical pediatric inpatients. The study assessed the impact of using rES/rGS as a first-tier test for children.
businesswire.com
- 1 week ago
GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last?
GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
zacks.com
- 2 weeks ago
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
NEW YORK , June 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
prnewswire.com
- 2 weeks ago
GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announces the American Academy of Pediatrics (AAP) issued updated guidance to now recommend exome and genome sequencing as first-tier tests for children with global developmental delay (GDD) or intellectual disability (ID) in most circumstances because of superior diagnostic yield and higher cost-effectiveness if pursued earlier in the diagnostic process2. For more.
businesswire.com
- 2 weeks ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
globenewswire.com
- 2 weeks ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
globenewswire.com
- 2 weeks ago
8. Profile
Summary
GeneDx Holdings Corp. WGS
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 2.61 B
Dividend Yield
0.00%
Description
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Contact
North Tower, Stamford, CT, 06902
http://www.genedx.com
IPO
Date
Nov. 4, 2020
Employees
1000
Officers
Dr. Bryan M. Dechairo Ph.D.
Chief Operating Officer
Dr. Martin G. Reese Ph.D.
President of Fabric Genomics
Ms. Heidi C. Chen J.D.
Chief Legal Officer
Ms. Katherine A. Stueland
President, Chief Executive Officer & Director
Ms. Jami Biliboaca
Head of People Strategy
Ms. Melanie Duquette
Chief Growth Officer
Mr. Kevin Feeley CPA
Chief Financial Officer